24 C
Vientiane
Wednesday, April 30, 2025
spot_img
Home Blog Page 631

Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer

SUZHOU, China, Feb. 6, 2025 /PRNewswire/ — Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to initiate a Phase III clinical study (Study ID: JSKN003-301). The study aims to compare the efficacy and safety of JSKN003 versus trastuzumab emtansine (T-DM1) for the treatment of HER2-positive advanced breast cancer. This marks the third Phase III clinical study initiated for JSKN003, following the trials in HER2 low-expressing breast cancer and platinum-resistant ovarian cancer.

Breast cancer is one of the most common malignant tumors among women worldwide and the most prevalent cancer in women in China. HER2-positive breast cancer accounts for 20% to 25% of all breast cancer cases in China, and it is the most aggressive and highly malignant subtype, prone to recurrence, metastasis, and worse prognosis. In recent years, targeted therapies and combination treatments have emerged and significantly improved the diagnosis and treatment of HER2-positive breast cancer. However, recurrent and metastatic breast cancer still poses a severe threat to patients’ health, with a significant unmet clinical need.

JSKN003 is an anti-HER2 bispecific ADC developed inhouse with Alphamab’s proprietary Glycan-specific conjugation platform. The antibody molecule KN026 is site-specifically modified via enzyme catalytic reaction and click chemistry to achieve a drug-to-antibody ratio (DAR) of approximately 4. It can bind HER2 on the surface of tumor cells, and release topoisomerase I inhibitors (TOPIi) through cellular endocytosis, thereby exert anti-tumor effects. Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window. Multiple clinical studies at various stages of JSKN003 conducted in China and Australia have demonstrated favorable tolerability and safety profile, with promising efficacy of JSKN003 in heavily pretreated patients with advanced solid tumors, especially in patients with HER2-expressing breast cancer, platinum-resistant ovarian cancer (PROC), or high HER2-expressing solid tumors.

JSKN003-301 is a randomized, controlled, open-label, multicenter, Phase III clinical study aimed at evaluating the efficacy and safety of JSKN003 compared to emtansine (T-DM1) in the treatment of patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who have previously received trastuzumab or taxane-based therapies. The primary endpoint of the study is progression-free survival (PFS) as assessed by the Blinded Independent Review Committee (BIRC).

About JSKN003

JSKN003 is an anti-HER2 bispecific antibody-drug conjugate (bis-ADC), which is developed inhouse with Alphamab’s proprietary Glycan-specific conjugation platform. JSKN003 can bind HER2 on the surface of tumor cells and release topoisomerase I inhibitors (TOPIi) through cellular endocytosis, thereby exert anti-tumor effects. Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window.

Multiple clinical studies at various stages of JSKN003 are currently being conducted in China and Australia. Clinical research results have demonstrated favorable tolerability and safety profile, with promising efficacy of JSKN003 in heavily pretreated patients with advanced solid tumors, especially in patients with HER2-expressing breast cancer, platinum-resistant ovarian cancer (PROC), or high HER2-expressing solid tumors.

In September 2024, the Company entered a licensing agreement with JMT-Bio Technology Co., Ltd. (“JMT-Bio”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (stock code: 1093.HK), pursuant to which, JMT-Bio was granted the exclusive license and sublicense rights to develop, sell, offer for sale and commercialize JSKN003, for the treatment of tumor-related indications (the “Field”) in mainland China (excluding Hong Kong, Macau or Taiwan) (the “Territory”) and become the sole marketing authorization holder for JSKN003 for the Field in the Territory. Alphamab retains the sole right to supply JSKN003.

About Alphamab Oncology

Alphamab Oncology is a leading biopharmaceutical company committed to the development, manufacturing, and commercialization of cutting-edge biotherapeutics for the treatment of cancer. On December 12, 2019, the company was successfully listed on the Main Board of the Hong Kong Stock Exchange, trading under the stock code 9966.

Our integrated platform seamlessly combines research, development, and manufacturing capabilities for biologics. We take pride in our extensive intellectual property portfolio, which encompasses protein/antibody engineering, antibody screening, and multi-module/multi-functional antibody modification.

Distinguished by a globally competitive pipeline, Alphamab Oncology specializes in antibody-drug conjugation (ADC), single domain antibody, and bispecific antibodies. Notably, Envafolimab, the world’s first subcutaneously injectable PD-L1 inhibitor, was approved by Chinese authorities in 2021, making a significant breakthrough in the convenience and accessibility of cancer treatment. Three assets are currently undergoing Phase III or pivotal clinical trials, and several other bispecific ADC new drug candidates are in early clinical stage. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, Arrivent, and Glenmark.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is dedicated to the development of safe, effective and affordable drugs, leveraging a global competitive edge.

Forbes Names Bitget Among World’s Most Trusted Crypto Exchanges

VICTORIA, Seychelles, Feb. 6, 2025 /PRNewswire/ — Bitget, a top global cryptocurrency exchange and Web3 innovator, has been ranked #8 on Forbes’ 2025 list of the World’s Most Trustworthy Crypto Exchanges. This recognition highlights Bitget’s rapid growth and user-focused innovations as it solidifies its position as a leader in the digital asset industry.

Forbes Names Bitget Among World’s Most Trusted Crypto Exchanges
Forbes Names Bitget Among World’s Most Trusted Crypto Exchanges

Growth Highlights

Bitget’s user base grew by 400% in 2024, surpassing 100 million registered users by December. Spot trading volume surged from $160 billion in Q1 to $600 billion by year-end, driven by platform upgrades and strategic partnerships. Recent initiatives include collaborations with Turkish national athletes, Spain’s legendary LALIGA football league, and the onboarding of key executives to strengthen global operations.

Global Expansion & Compliance

Bitget is accelerating its worldwide presence through localized services, educational programs, and regulatory compliance. The exchange now offers simplified onboarding, local currency support, and region-specific customer assistance. Recent milestones include securing a UK regulatory approval, obtaining a license in El Salvador, and launching a tailored platform in Vietnam.

Market Leadership

According to industry data, Bitget’s combined spot and derivatives market share reached 10.5% in 2024, reflecting a 4.05% increase. The Bitget Token (BGB) also outperformed expectations, rising over 1,000% in value last year. Plans to expand BGB’s utility—including supply reductions and new ecosystem integrations—aim to sustain long-term growth for users.

Trust

Bitget provides proof of reserves and a $600 million Protection Fund, the largest self-funded safeguard in the industry. Its inclusion on Forbes’ list underscores its reputation for reliability and innovation.

About Bitget

Founded in 2018, Bitget serves over 100 million users across 150+ countries. The platform offers smart trading tools, real-time market access, and Bitget Wallet, a leading multi-chain Web3 solution for swaps, NFTs, and decentralized apps. Bitget’s partnerships with sports leagues and athletes aim to inspire broader crypto adoption worldwide.

Learn More: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet

Risk Notice: Cryptocurrency investments carry volatility and risk. Investors should assess their financial capacity and seek independent advice. Past performance does not guarantee future results.

AIM Vaccine mRNA RSV Vaccine Submits for Clinical Trials in the U.S.

Multiple Institutions Give AIM a “Buy” Rating


HONG KONG SAR – Media OutReach Newswire – 5 February 2025 – AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to the U.S. Food and Drug Administration (FDA). The vaccine has demonstrated significantly higher humoral and cellular immunity compared to internationally marketed products. If the product progresses smoothly, it will accelerate AIM Vaccine’s international expansion and contribute to substantial performance growth.

In preclinical animal trials, third-party testing results showed that AIM Vaccine’s mRNA RSV vaccine achieved significantly higher levels of specific IgG antibody titers, live-virus neutralizing antibody potency, and specific T-cell immunity compared to internationally marketed mRNA RSV control vaccines.

This announcement highlights AIM Vaccine’s innovative capabilities and underscores the acceleration of its internationalization efforts, which have been recognized by multiple institutions.

Recently, FOSUN INTERNATIONAL SECURITIES initiated coverage of AIM Vaccine, assigning a “Buy” rating with a 12-month target price of HKD 11.0. The report cited the company’s strong product pipeline, technological leadership, and potential for international growth as key factors. Similarly, SDICSI released a research report predicting that AIM Vaccine will launch 1-2 products annually over the next three years. If the products in development gain approval and progress smoothly in international markets, they are expected to drive new performance growth and expand market potential. SDICSI also assigned a “Buy” rating with a target price of HKD 9.5.

FOSUN INTERNATIONAL SECURITIES’s analysis indicates that the Chinese vaccine market is evolving in line with global trends, where high-value products and leading companies dominate. With its differentiated advantages, AIM Vaccine is poised to secure a leading position in the domestic market while achieving scalable expansion internationally. Additionally, the company’s comprehensive and iterative product portfolio is expected to enhance its market share, pricing power, and profitability, further supporting long-term growth.

The report also emphasized that AIM Vaccine, with its diversified product portfolio, technological strengths, and global expansion strategy, presents an attractive investment opportunity for investors. With a series of high-value products set to launch and profitability expected to rebound from 2025 onwards, the company is positioned for strong growth and potential valuation reassessment.

Globally, there are currently no approved antiviral drugs for RSV available for clinical use. Vaccination for active immune prophylaxis remains the most effective means to prevent severe RSV infections. No RSV vaccines have been approved for marketing in PRC. In 2023, global sales of RSV vaccines reached USD 2.46 billion, and according to industry consultants, the market size is expected to grow to approximately USD 16.7 billion by 2030.

The mRNA vaccine field is still wide open with plenty of opportunities, as there are few competitors globally. AIM Vaccine is one of the earliest companies in PRC to develop mRNA vaccine products and is among the first domestic vaccine enterprises to obtain independent patents for mRNA technology. The company has established a mature mRNA vaccine R&D system and has developed multiple mRNA candidate vaccines, including vaccines for shingles, rabies, and influenza, in addition to the mRNA RSV vaccine.
Hashtag: #AIMVaccine

The issuer is solely responsible for the content of this announcement.

Expanding Expertise in Energy: SMART ENERGY WEEK [February] 2025 reveals conference lineup & new exhibit area

TOKYO, Feb. 6, 2025 /PRNewswire/ — With its strong belief in the role of renewable energy towards a progressive future, SMART ENERGY WEEK [February] continues to enrich industry expertise with the launch of its much-awaited conference programme for 2025, alongside a new exhibit area for photovoltaics.


This renowned show in the energy sector, organised by RX Japan Ltd., is set to welcome attendees on February 19–21, 2025, at Tokyo Big Sight. The Spring edition will also bring leading industry brands to exhibit, such as Huawei Technologies Co. Ltd., Mitsubishi Heavy Industries Ltd., Vento Energy Support, and Windy Network Inc., to name a few.

Thought Leaders & Valuable Business Insights

SMART ENERGY WEEK [February] recently unveiled an impressive lineup of speakers for its conference programme.

All sessions promise visitors an opportunity to listen to experts on where the industry is headed so that they may leverage insights to elevate expertise and business. A simultaneous AI translation system is also available for real-time learning and accessibility.

General topics to be discussed are:

  • innovations in batteries and how they can support societal sustainability,
  • the latest trends in fuel cells and hydrogen,
  • current practices in biomass energy production,
  • the expansion of solar power generation technology,
  • turning thermal power generation carbon-neutral,
  • and the construction of power systems in the face of AI.

Keynote speeches will also be held across the 3-day event on climate change and its impacts on energy, as well as on adapting circular economies and managing decarbonisation efforts in lieu of the 2050 carbon-neutrality goals.

Industry leaders and authorities alike will spearhead these sessions. Some notable speakers are Ryota Kondo from the Ministry of the Environment Government of Japan, Akiyo Miyakawa from the Development Bank of Japan Inc., Tomoko Morikawa from the Mitsubishi Heavy Industries, Ltd., and Daisuke Hirota from the Ministry of Economy, Trade and Industry.

Diversifying Its Reach: Launch of the BIPV World

Attendees will also be introduced to a new specialised exhibiting area this 2025, located in the PV Expo show zone—BIPV World.

This special programme is co-organised with the Japan Photovoltaic Energy Association, where products, services, and technologies concerned with building-integrated photovoltaics will be displayed.

BIPV or Building-Integrated Photovoltaics, are next-level solar power equipment. Instead of just panels, BIPVs are actual parts of the building structure that store and generate energy. This can be in the form of flooring, glazing, awnings, integrated roofs, and many more.

At SMART ENERGY WEEK [February], buyers of BIPV come from sectors such as housing manufacturing and building, architectural firms, construction, trading companies, government offices, and commercial facilities.

Exhibitors, on the other hand, for this specialised area deal with the following:

  • Perovskite Solar Cells
  • Solar Cell-Integrated Glass Building Materials
  • Solar Cell-Integrated Exterior Wall Materials
  • Solar Cell-Integrated Roofing Materials
  • Colouring and Decorative Films
  • Waterproofing and Insulation Technology
  • Energy Management System
  • Power Conversion and Inverters
  • Mounting Systems and Installation Technology

BIPV will host seminars daily across the expo’s 3-day event for exhibitors to introduce their top-calibre products and services. This is alongside real-time business meetings, specifically tailored to technical proposals, design consultations, equipment & materials specifications, and discussions for delivery schedules.

Expanding for Progress

This show zone expansion and continuous investment of value to conferences (and the market insights it offers professionals), demonstrates the unfailing ability of SMART ENERGY WEEK [February] to find the pulse of the industry and where it is headed.

Enriching the expertise that it provides stakeholders in the energy sector remains the expo’s priority, as it recognises the indispensable role of delivering timely and quality innovations and information to business growth and success.

To know more about SMART ENERGY WEEK [February], please visit this sitehttps://www.wsew.jp/spring/en-gb/register.html?cat=visitor&ct=U2FsdGVkX18LmRNiENF5[…]I=&utm_source=pr&utm_medium=banner&utm_campaign=spring_taiwanen

About RX (Reed Exhibitions)

RX is in the business of building businesses for individuals, communities, and organisations. We elevate the power of face-to-face events by combining data and digital products to help customers learn about markets, source products, and complete transactions at approximately 400 events in 22 countries across 42 industry sectors. RX is passionate about making a positive impact on society and is fully committed to creating an inclusive work environment for all our people. RX is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.rxglobal.com 

About RX Japan

RX Japan organises 90 exhibitions, composed of 372 sub-exhibitions, annually at large exhibition halls such as Tokyo Big Sight, Makuhari Messe, and Intex Osaka across a wide variety of 39 fields, including jewellery, fashion, gift items, electronics, energy, IT, cosmetics, and medical. Visit the RX Japan website for more details.

CONTACT: Smart Energy Week Show Management, wsew.jp@rxglobal.com 

Medidata Advances New Frontiers for Life Sciences Through Patient-Centric Experiences, AI-Powered Innovations, and New Patient Engaging Alliances

In the era of the generative economy, Medidata is transforming how industries are empowering patients with new cure and care experiences and lifelong engagement

SINGAPORE, Feb. 6, 2025 /PRNewswire/ — Medidata, a Dassault Systèmes brand, reaffirms its vision and commitment to advancing the life sciences industry and transforming patient experiences across the entire clinical development process, from pre-trial planning, to post-trial outcomes, and ongoing patient care. With advanced technologies, such AI and virtual twins, Medidata enables biopharmaceutical companies, researchers, and patients to accelerate therapy development and improve patient lives.

A trusted partner to 19 of the top 20 pharmaceutical companies, Medidata continues to break ground with new categories of critical patient-centric experiences, seamlessly integrating AI into its suite of solutions: elevating data utilization, streamlining research studies, and transforming the patient journey. These generative experiences leverage synthetic data to create simulations of patients representing key virtual cohorts, helping sponsors reduce exposure to experimental therapies and improve trial performance. Fueled by the largest patient-level historical clinical trial trustable data set in the world, Medidata’s bundled offerings for specialized therapeutic areas amplify Dassault Systèmes’ knowledge and know-how impact and value for treatments.

“Dassault Systèmes is deeply committed to advancing the life sciences industry, and Medidata is well positioned to lead this mission,” noted Pascal Daloz, CEO, Dassault Systèmes. “A shift to value-based experiences, powered by premier AI across the entire Medidata portfolio, is aligned with our vision of leveraging virtualization to enhance people’s lives.”

Driven by its purpose to empower the life sciences and healthcare stakeholders, Medidata is also establishing new patient health ecosystems. High quality patient data collected using biosensors is helping shape a 360-degree clinical and medical view of the patients, laying down the foundation for creating virtual twins of individuals, pathologies and journeys. In addition, the brand is positioned to engage patients beyond the clinical trial setting through its collaborations with innovative medical technology companies, supporting treatment plans with leading-edge virtual approaches, such as digital therapeutics, and paving the way to Virtual + Real (V+R) treatments.

“Medidata is at the forefront of a critical shift in the life sciences sector,” said Anthony Costello, CEO, Medidata. “By harnessing AI-powered solutions and partnering with visionaries, we aren’t just accelerating and improving clinical studies, but also driving a lasting impact on patients’ lives well beyond the trial.”

Medidata – along with other key Dassault Systèmes brands, such as BIOVIA, SIMULIA, and DELMIA – has significantly shaped the life sciences ecosystem, connecting research, drug discovery, R&D, clinical research, laboratories activities, manufacturing, quality, and patient care. In 2024 alone, Medidata added 300+ new customers, including major pharmaceutical firms and research organizations such as Sanofi, Eisai, and PPD, the clinical research business of Thermo Fisher Scientific Inc. These organizations are driving breakthroughs in research, from developing the first non-opioid drug for neuropathic pain in over 20 years to integrating biometric solutions in studies and advancing an mRNA vaccine for RSV, a respiratory virus.

As Medidata continues to innovate within its broad portfolio, ranging from industry leading solutions designed for clinical researchers to supporting ongoing patient care and lifelong engagement, the company is committed to the metamorphosis of its customers in the Age of the Generative Economy, enabling new inclusive and empowering relationships with patients, fostering new health ecosystems, and unleashing new defining clinical and medical knowledge, know-how, and innovations for the sector. To learn more about Medidata’s portfolio, please visit the website.

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 35,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress.  Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens.  With Dassault Systèmes’ 3DEXPERIENCE platform, 350,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact.  For more information, visit: www.3ds.com

Inflation Rate Eases to 15.5% in January

Inflation Rate Eases to 15.5% in January

Laos’ inflation rate eased to 15.5 percent in January, compared to 16.9 percent in December 2024, according to a report by the Lao Statistics Bureau. 

Thailand to Launch New Digital Arrival Card

Thailand to End up Paper Arrival Card and Transform to Digital System (Photo: The Nation Thailand)

Starting 1 May, Thailand’s Ministry of Tourism and Sports will introduce the digital arrival card (TDAC), also known as the “TM.6 online” system, for all foreign passport holders, replacing the traditional paper form.

Amadeus and Traveloka strengthen travel technology partnership

SINGAPORE, Feb. 6, 2025 /PRNewswire/ — Amadeus, the leading global travel technology company, has strengthened its partnership with Traveloka, Southeast Asia’s top travel platform. This agreement sees Amadeus’ already extensive footprint in the region expand as the two organizations work to deliver a more personalized travel experience through technology.

In line with Traveloka’s focus on empowering consumers to explore, book, and enjoy a wide range of travel products, the collaboration will expand Traveloka’s growing business by using Amadeus’ technology to enhance the travel experience of its customers. Travelers will enjoy new services to help them explore and book a wide range of travel products, including fully customized flight search technology and servicing capabilities.

Amadeus and Traveloka will also work together to bring more NDC enabled content to its travel platform so it can provide its customers with competitive prices and truly tailored offers. Traveloka will also benefit from advanced servicing capabilities that are integrated into its existing technology stack.

Caesar Indra, President, Traveloka says, “Collaborating with Amadeus allows us to leverage its expertise and technology to provide better services to our customers. This partnership is a significant step in our growth strategy, and we are confident in Amadeus’ ability to provide a smoother and more seamless travel experience for our customers.”

Javier Laforgue, EVP & Managing Director Asia-Pacific, Amadeus says, “We are pleased to expand our collaboration with Traveloka to bring our innovative technology solutions to the Asia Pacific region. This partnership will not only enhance Traveloka’s services but also strengthen Amadeus’ position as a regional leader in travel technology. We are committed to delivering cutting-edge technology solutions that will drive growth and innovation in the travel industry. Together, we will create a seamless and enhanced travel experience for Traveloka’s customers across the APAC region and beyond.”

Notes to the editors:

About Amadeus

Amadeus makes the experience of travel better for everyone, everywhere by inspiring innovation, partnerships and responsibility to people, places and planet.

Our technology powers the travel and tourism industry. Inspiring more open ways of working. More connected ways of thinking, centered around the traveler. Our open platform connects the global travel and hospitality ecosystem. From startups to big industry players and governments too. Together, redesigning the travel of tomorrow.

We are working to make travel a force for social and environmental good. A collective responsibility to protect and improve the people and places we visit, ensuring travel continues to make positive contribution to our world.

We apply innovation to meet new needs, to solve real challenges. Our truly diverse global workforce, made up of 150 nationalities, is passionate about travel and technology.

We are an IBEX 35 company, listed on the Spanish Stock Exchange under AMS.MC. We have also been recognized by the Dow Jones Sustainability Index for the last 13 years.

Amadeus. It’s how travel works better.

Learn more about Amadeus at www.amadeus.com

About Traveloka

Founded in Indonesia in 2012, Traveloka has operations in Australia, Malaysia, the Philippines, Singapore, Thailand, and Vietnam. With nearly 140 million app downloads and more than 40 million monthly active users, Traveloka stands as one of the most popular travel apps in the region.